GABA-A alpha-5 modulator to help memory and thinking in early Alzheimer’s stages
Official title: Preclinical and early clinical development of a GABA-A a5 PAM
Funded at Agenebio, INC. · NIH-11529495 · Data updated 2026-11-12
A new, oral drug aimed at soothing overactive brain circuits may help memory and thinking in people at early risk of developing Alzheimer’s dementia.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Agenebio, INC. NIH-funded |
| Lab location | 1 site (Baltimore, UNITED STATES) |
| Project start | September 1, 2022 |
| Project end | August 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $203,500 |
| NIH project number | 3U01AG074950-04S1 |
| Project ID | NIH-11529495 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with Mild Cognitive Impairment due to Alzheimer’s disease or those at high risk for progressing to Alzheimer’s dementia.
✕Less likely to help
Individuals without early cognitive impairment or without the specific hippocampal overactivity profile may not experience benefit.
What this research studies
This project develops a potent, selective GABA-A alpha-5 positive allosteric modulator (PAM) that could reduce excessive activity in the hippocampus, a brain area linked to memory problems in early Alzheimer’s disease. The work moves from preclinical studies toward early clinical testing, focusing on safety, dosing, and signals of cognitive benefit in people with Mild Cognitive Impairment due to Alzheimer’s disease. Researchers collaborate with a biotech sponsor to translate science into a potential treatment that targets brain circuitry rather than broad brain function. The overall goal is to offer a new option for people at high risk of dementia who currently have few effective therapies.
Why it matters
Potential benefit: If successful, the program could provide a new therapeutic approach to slow or improve memory and cognitive function in people at risk for Alzheimer's dementia.
How similar studies have gone: Previous studies in animals and humans suggest that reducing hippocampal overactivity can improve memory, supporting this approach as promising but still experimental.
Where this research is happening
-
Agenebio, INC.
Baltimore, United States Active
Researchers
- Principal investigator: Payie, Kenneth G — Agenebio, INC.
- Study coordinator: Payie, Kenneth G
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.